Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Antitumor Effects and Tumor-specificity of Guaiazulene-3-Carboxylate Derivatives Against Oral Squamous Cell Carcinoma In Vitro

MICHITO TERATANI, SHOUTA NAKAMURA, HIROSHI SAKAGAMI, MASAKAZU FUJISE, MASASHI HASHIMOTO, NORIYUKI OKUDAIRA, KENJIRO BANDOW, YOSUKE IIJIMA, JUNKO NAGAI, YOSHIHIRO UESAWA and HIDETSUGU WAKABAYASHI
Anticancer Research September 2020, 40 (9) 4885-4894; DOI: https://doi.org/10.21873/anticanres.14491
MICHITO TERATANI
1Faculty of Science, Josai University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHOUTA NAKAMURA
1Faculty of Science, Josai University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI SAKAGAMI
2Meikai University Research Institute of Odontology (M-RIO), Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAKAZU FUJISE
1Faculty of Science, Josai University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASASHI HASHIMOTO
1Faculty of Science, Josai University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIYUKI OKUDAIRA
3Department of Biochemistry, Teikyo University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENJIRO BANDOW
4Division of Biochemistry, Meikai University School of Dentistry, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSUKE IIJIMA
5Department of Oral and Maxillofacial Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUNKO NAGAI
6Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIHIRO UESAWA
6Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDETSUGU WAKABAYASHI
1Faculty of Science, Josai University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hwaka@josai.ac.jp sakagami@dent.meikai.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: The aim of this study was to investigate the antitumor potential of guaiazulene-3-carboxylate derivatives against oral malignant cells. Materials and Methods: Twelve guaiazulene-3-carboxylate derivatives were synthesized by introduction of either with alkyl group [1-5], alkoxy group [6, 7], hydroxyl group [8, 9] or primary amine [10-12] at the end of sidechains. Tumor-specificity (TS) was calculated by the ratio of mean 50% cytotoxic concentration (CC50) against 3 human oral mesenchymal cell lines to that against 4 human oral squamous cell carcinoma (OSCC) cell lines. Potency-selectivity expression (PSE) was calculated by dividing TS value by CC50value against OSCC cell lines. Cell cycle analysis was performed by cell sorter. Results: [6, 7] showed the highest TS and PSE values, and induced the accumulation of both subG1 and G2/M cell populations in HSC-2 OSCC cells. Quantitative structure-activity relationship analysis demonstrated that their tumor-specificity was correlated with chemical descriptors that explain the 3D shape, electric state and ionization potential. Conclusion: Alkoxyl guaiazulene-3-carboxylates [6, 7] can be potential candidates of lead compound for developing novel anticancer drugs.

  • QSAR
  • guaiazulene-3-carboxylate
  • OSCC
  • tumor-specificity
  • molecular shape
  • ionization potential

Azulene (Figure 1A) is an isomer of naphthalene having a dipole moment and a resonance energy with intermediate values between that of benzene and naphthalene; it is considerably more reactive, when compared with these two arenes (1-4). Among the 962 papers cited in PubMed regarding azulenes, most of them have focused on its chemistry, followed by biological activity, while few papers have focused on dentistry and oral application. Sodium azulene sulfonates have been reported to be effective for the treatment of oral mucositis (5) and oral lichen planus (6), possibly due to their antioxidant and anti-inflammatory activities (7, 8). In contrast, much reduced numbers of papers of guaiazulene (Figure 1B), a lipophilic azulene derivative, have been published, approximately half of which have dealt with its chemistry. Guaiazulenes also have antioxidant and anti-inflammatory activities (9-11) and a few papers have dealt with the treatment of oral diseases (12, 13).

As far as we know, anticancer potential of guaiazulene derivatives against human oral malignant cells has not yet been reported. This urged us to initiate the investigation of 10 alkylaminoguaiazulenes (Figure 1C) (14), 10 guaiazulene amides (Figure 1D) (15) and 14 azulene amide derivatives without or with 7-isopropylgroup (Figure 1E, F) (16). We have reported that the introduction of an isopropyl group in the seven-member ring and an amide group rather than alkylamino group in the five-member ring of guaiazulene increased the specific cytotoxicity against malignant cells over non-malignant cells (14-16) (Figure 1). Furthermore, quantitative structure-activity relationship (QSAR) analyses demonstrated the tight correlation of their tumor-specificity with hydrophobicity and molecular shape (15, 16).

The aim of the present study was to search for more tumor-selective guaiazulene derivatives. For this purpose, we synthesized a total of 12 guaiazulene-3-carboxylate derivatives [1-12] (Figure 1), in which alkyl group [1-5], alkoxy group [6, 7], hydroxyl group [8, 9] and primary amine [10-12] were introduced at the end of sidechain (Figure 1G), and investigated their tumor-specificity using four human oral squamous cell carcinoma (OSCC) cell lines and three human normal oral cells. We also investigated the effects of these compounds on cell cycle phase distribution, in OSCC cells.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Structure of azulene (A), guaiazulene (B), alkylaminoguaiazulenes (C), guaiazulene amides (D), azulene amide derivatives without (E) or with 7-isopropylamino group (F), and 12 guaiazulene-3-carboxylate derivatives used in this study (G).

Materials and Methods

Materials. The following chemicals were obtained from the indicated companies: Dulbecco's modified Eagle's medium (DMEM) from Gibco BRL, Grand Island, NY, USA); fetal bovine serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) from Sigma-Aldrich Inc., St. Louis, MO, USA; 5-fluorouracil (5-FU) from Kyowa, Tokyo, Japan; cisplatin (CDDP) from Nichi-Iko Pharmaceutical Co. Ltd., Toyama, Japan; carboplatin (CBDCA) from Sawai Pharmaceutical Co. Ltd., Osaka, Japan; Paclitaxel (PTX) from Nipro Corporation, Osaka, Japan; dimethyl sulfoxide (DMSO) and actinomycin D (Act. D) from Wako Pure Chem. Ind., Osaka, Japan. Regarding consumables, 100-mm treated culture dishes were purchased from TrueLine, Nippon Genetics Co., Ltd, Tokyo, Japan and 96-well plates from Techno Plastic Products AG, Trasadingen, Switzerland.

Synthesis of guaiazulene-3-carboxylate derivatives. Methyl guaiazulene-3-carboxylate [1], ethyl guaiazulene-3-carboxylate [2], n-propyl guaiazulene-3-carboxylate [3], isopropyl guaiazulene-3-carboxylate [4], n-butyl guaiazulene-3-carboxylate [5], 2-methoxyethyl guaiazulene-3-carboxylate [6], 2-ethoxyethyl guaiazulene-3-carboxylate [7], 2-hydroxyethyl guaiazulene-3-carboxylate [8], 2-(2-hydroxyethoxy)ethyl guaiazulene-3-carboxylate [9], 2-aminoethyl guaiazulene-3-carboxylate [10], 3-aminoprpyl guaiazulene-3-carboxylate [11], 4-aminobutyl guaiazulene-3-carboxylate [12] (Figure 1G) were synthesized, according to previous reports (6, 17, 18). N-(2-methoxyethyl)guaiazulenecarboxamide [X] was synthesized as previously described (15). All compounds were dissolved in DMSO at 40 mM and stored at −20°C before use.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Cytotoxicity and tumor-specificity (evaluated by TS and PSE values) of 12 guaiazulene-3-carboxylate derivatives against human oral squamous cell carcinoma (OSCC) cell lines and human normal oral cells (normal).

Cell culture. Human normal oral cells [gingival fibroblast (HGF), periodontal ligament fibroblast (HPLF), pulp cell (HPC)] (19) at 12~20 population doubling level (PDL) and OSCC cell lines (Ca9-22, HSC-2, HSC-3, HSC-4) (Riken Cell Bank, Tsukuba, Japan) were cultured at 37°C in DMEM supplemented with 10% heat-inactivated FBS and antibiotics under humidified 5% CO2 atmosphere, as described previously (14-16).

Assay for cytotoxic activity. Cells were inoculated at 2×103 cells/0.1 ml in a 96-microwell plate. After 48 h, the medium was replaced with 0.1 ml of fresh medium containing various concentrations of test compounds. Control cells were treated with the same amounts of DMSO present in each diluent solution. Cells were incubated for 48 h and the relative viable cell number was then determined by the MTT method, as described previously (14-16). The CC50 was determined from the dose–response curve of triplicate samples.

Calculation of tumor-selectivity index (TS). TS(mean) was calculated as the ratio of the mean CC50 value for the human normal oral cells (HGF+HPLF+HPC) to that for the OSCC cell lines (Ca9-22+HSC-2+HSC-3+HSC-4). Moreover, TS was calculated for cells derived from gingival tissue (20), and as the ratio of CC50 (HGF) to CC50 (Ca9-22) (TS(HGF/Ca9-22)).

Calculation of potency-selectivity expression (PSE). PSE was calculated by the formula: (TS/CC50) ×100 (11, 12).

Cell cycle analysis. Cells (approximately 106 cells) were harvested, fixed, treated with ribonuclease A, stained propidium iodide, filtered through cell strainers and then were subjected to cell sorting (SH800 Series, SONY Imaging Products and Solutions Inc., Atsugi, Kanagawa, Japan) and cell cycle analysis (Cell Sorter Software version 2.1.2., SONY Imaging Products and Solutions Inc), as described previously (16).

Calculation of chemical descriptors. pCC50 (i.e., the −log CC50) was used for the comparison of the cytotoxicity between the compounds, since the CC50 values had a distribution pattern close to a logarithmic normal distribution. The mean pCC50 values for normal cells and tumor cell lines were defined as N and T, respectively (15, 16) (Table II). The 3D-structure of each chemical structure was drawn by Marvin Sketch (MarvinSketch 18.10.0, ChemAxon, Budapest, Hungary, http://www.chemaxon.com), and optimized by CORINA Classic (Molecular Networks GmbH, Nürnberg, Germany) with forcefield calculations (amber-10: EHT) in Molecular Operating Environment (MOE) version 2019.0101 (Chemical Computing Group Inc., Quebec, Canada) and Dragon (Dragon 7 version 7.0.2, Kode srl., Pisa, Italy).

Statistical analysis. Each experimental value was expressed as the mean±standard deviation (SD) of triplicate or quadruplicate measurements. The statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Bonferroni's post-hoc test for multiple comparisons. The correlation between chemical descriptors and cytotoxicity or tumor specificity index was investigated using linear regression analyses. The significance level was set at p<0.05. Statistical analysis was performed using the JMP Pro version 14.3.0 software (SAS Institute Inc., Cary, NC, USA).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Top six chemical descriptors that correlate with cytotoxicity to tumor cells, normal cells and tumor-specificity (having the highest r2 values).

Results

Cytotoxicity and tumor-specificity. Twelve guaiazulene-3-carboxylate derivatives used in this study were classified into four groups: alkyl guaiazulene-3-carboxylates [1-5], alkoxyl guaiazulene-3-carboxylates [6, 7], hydroxyalkyl guaiazulene-3-carboxylates [8, 9] and aminoalkyl guaiazulene-3-carboxylates [10-12] (Figure 1G). We compared their cytotoxic activity against four human oral squamous cell carcinoma (OSCC) cell lines (Ca9-22, HSC-2, HSC-3, HSC-4) and three normal oral cells (HGF, HPLF, HPC), by comparing the 50% cytotoxic concentration (CC50) determined from the dose-response curve (Table I). We have adopted 48 h treatment time, based on our observation that significant (p<0.05) cytotoxicity of compounds [6, 7] appeared 3 h after treatment, reaching the plateau level after 24~48 h (Figure 2). We have repeated the same experiments 3 times. The mean values of CC50, tumor-selectivity index (TS), and potency-selectivity expression (PSE) of these twelve compounds, as well as of positive controls (5-FU, CDDP, and CBDCA) obtained from these 3 independent experiments are listed in Table I. Most of the compounds [1, 3, 4-6, 8-12] showed significantly higher cytotoxicity against OSCC cell lines, compared to normal cells (p<0.05). Among the 12 studied guaiazulene-3-carboxylates, two alkoxyl guaiazulene-3-carboxylates [6, 7] (TSmean=4.4±0.2; PSE=13.0±1.9) showed the highest TS values than five alkyl guaiazulene-3-carboxylates [1-5], two hydroxyalkyl guaiazulene-3-carboxylates [8, 9], and three aminoalkyl guaiazulene-3-carboxylates [10-12] (Table I). Moreover, both [6, 7] showed higher TS value than CDDP and CBDCA (TSmean=2.2±1.5 and 2.4±1.1, respectively), and had PSE(mean) values comparable to that of 5-FU (13.4±6.5). Regarding TS(HGF/Ca9-22) and PSE(HGF/Ca9-22), high SD values were observed, possibly due to a cytostatic, rather than cytotoxic inhibition of cell proliferation, causing variations of CC50 values in each experiment (Table I).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Time- and dose-response of cytotoxicity induction by [6] and [7]. HSC-2 cells were incubated for 1, 3, 6, 24 or 48 h with the indicated concentrations of [6] or [7], and then the viable cell number was determined by MTT method. Each value represents mean±SD of triplicate assays. The differences between control and treated groups were evaluated by one-way analysis of variance (ANOVA) followed by Bonferroni's post-hoc test for multiple comparisons. *p<0.05 compared with control.

Induction of apoptosis and G2/M arrest. Light microscopical observation (Figure 3A) revealed that HSC-2 cells treated for 48 h with 20 μM of either [6] or [7] (slightly lower concentration of their CC50: 34.8 and 28.0 μM, Table I) were a mixture of shrunken and spread cells. Cell cycle analysis demonstrated that when compared to the control, [6, 7] significantly (p<0.05) reduced the G1 cell population, while increased the subG1 and G2/M phase cells, regardless of treatment time (24 h and 48 h) (Figure 3B, 3C). Actinomycin D (Act. D) increased more the percentage of subG1 cell population (p<0.05), but slightly reduced (p<0.05) the G2/M phase cells at 24 h (Figure 3B, 3C).

Computational analysis. The number of descriptors calculated from MOE and dragon were 344 and 5,255, respectively. As a result of excluding duplicates or descriptors with standard deviation of 0, the number of descriptors reduced to 264, 2,808, respectively. Among a total of 3,072 descriptors, the top six descriptors that showed the highest correlation coefficient (r2) to T, N and T-N are listed in Table II.

Cytotoxicity against human OSCC cell lines was correlated with descriptors BCUT_SLOGP_0 (r2=0.841, p<0.0001) (topological shape), Mi (r2=0.785, p=0.0001) (ionization potential), Mor24e (r2=0.757, p=0.0002) (3D shape and electric state), C% (r2=0.751, p=0.0003) (percentage of C atoms), Mor24i (r2=0.737, p=0.0003) (3D shape and ionization potential) and DISPi (r2=0.734, p=0.0004) (3D shape, size and ionization potential) (Figure 4).

Cytotoxicity against human normal oral mesenchymal cells was correlated with descriptors vsurf_Wp2 (r2=0.783, p=0.0001) (3D shape and polarizability), vsurf_IW1 (r2=0.753, p=0.0003) (3D shape and hydrophilicity), h_logD (r2=0.751, p=0.0003) (lipophilicity), vsurf_Wp3 (r2=0.740, p=0.0003) (3D shape and polarizability), RDF010s (r2=0.730, p=0.0004) (3D shape, size and electric state), and BCUT_SLOGP_0 (r2=0.678, p=0.0010) (topological shape) (Figure 5).

Tumor-specificity was correlated with descriptors MEcc (r2=0.696, p=0.0007) (3D shape), L3s (r2=0.692, p=0.0008) (3D shape, size and electric state), SpMAD_G/D (r2=0.678, p=0.0010) (3D shape and size), L3m (r2=0.649, p=0.0016) (3D shape, size and electric state), H2i (r2=0.648, p=0.0016) (3D shape and ionization potential) and TDB10i (r2=0.646, p=0.0016) (3D shape and ionization potential) (Figure 6).

These data suggest that both tumor-specificity and cytotoxicity of guaiazulene-3-carboxylate against OSCC correlate with 3D shape, electric state, and especially ionization potential.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Production of subG1 and G2/M cell populations by [6, 7]. HSC-2 cells were treated for 48 h or 24 h without (control) or with 20 μM [6], 20 μM [7] or 1 μM actinomycin D (Act. D) and then cell morphology (A) and cell cycle distribution (assessed by cell sorter) (B) were investigated. (C) Summary of the data of cell cycle distribution after 24 and 48 h. Each value represents mean±SD of triplicate assays. *p<0.05: Statistical significance from control. Scale of bar in (A): 100 μm.

Discussion

The present study demonstrated that among twelve guaiazulene-3-carboxylates, two alkoxyl guaiazulene-3-carboxylates [6, 7] showed higher tumor-specificity than five alkyl [1-5] and two hydroxyalkyl [8, 9] guaiazulene-3-carboxylates and three aminoalkyl guaiazulene-3-carboxylate carboxamides [10-12] (Table I). Both [6, 7] showed higher TS value than CDDP and CBDCA, and having comparable PSE value with 5-FU (Table I). Higher TS of [6, 7] might be explained by their 3D shape, electric state and especially ionization potential (Figure 6). This point was confirmed by the fact that when carboxylate portion in [6] was replaced with amide (N-(2-methoxyethyl)guaiazulenecarboxamide [X]), both TS and PSE were reduced (Figure 7). Guaiazulene has been reported to induce apoptosis in normal HGF (21). Therefore, compounds with much higher tumor-specificity should be synthesized.

PubMed search demonstrated that no paper published on the G2/M arrest by guaiazulene. Therefore, the present study demonstrated for the first time that [6, 7] induced cell shrinkage and subG1 cell accumulation (one of the markers of apoptosis) (22, 23), as well as G2/M cell accumulation (indication of mitotic arrest). We have recently reported that 7-isopropyl-3-methyl-N-propylazulene-1-carboxamide and 2-methoxy-N-pentylazulene-1-carboxamide, both of which do not have guaiazulene structure, did not induce the accumulation at G2/M, although they induced apoptosis in HSC-2 cells (16). Taken together, the presence of guaiazulene structure may be involved in G2/M arrest induction; however, further study is required to confirm the induction of apoptosis markers by [6, 7] and investigate the possible link of G2/M arrest and apoptosis induction.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Determination of coefficient between chemical descriptors and cytotoxicity of 12 guaiazulene-3-carboxylate derivatives against tumor cells (defined as T). The mean (pCC50 i.e., the −log CC50) values for tumor cell lines were defined as T.

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Determination of coefficient between chemical descriptors and cytotoxicity of 12 guaiazulene-3-carboxylate derivatives against normal cells (defined as N). The mean (pCC50 i.e., the −log CC50) values for normal cells were defined as N.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Determination of coefficient between chemical descriptors and tumor specificity of 12 guaiazulene-3-carboxylate derivatives (defined as T−N).

Figure 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 7.

Comparison of tumor-specificity (TS) values between [6] and N-(2-methoxyethyl)guaiazulenecarboxamide [X]. Four OSCC cell lines and three normal cells were incubated for 48 h with the indicated concentrations of [6] or [X] that was synthesized as previously described (15), and then TS and potency-selectivity expression (PSE) values were determined. Each value represents mean of triplicate assays.

We have recently reported that several G2/M blockers such as taxanes paclitaxel [Taxol®, the first microtubule stabilizing agent (24)] and docetaxel (25), and 3-styrylchromone derivatives [7-methoxy-3-[(1E)-2-phenylethenyl]-4H-1-benzopyran-4-one, 3-[(1E)-2-(4-hydroxyphenyl)ethenyl]-7-methoxy-4H-1-benzopyran-4-one] show very high TS values (>7267, >86122, 301 and 182, respectively) (26). However, many reports, including ours, demonstrated that microtubule-targeted agents have potent neurotoxicity, adversely affecting the quality of life of patients on a long-term basis (27-30). We have also reported that doxorubicin induced very potent keratinocyte toxicity by inducing apoptosis, characterized by the loss of cell surface microvilli, chromatin condensation, nuclear fragmentation and caspase-3 activation (31). Therefore, the possible side effects of guaiazulene-3-carboxylate derivatives such as neurotoxicity and keratinocyte toxicity should be evaluated.

In conclusion, the present study demonstrated for the first time that two guaiazulene-3-carboxylate derivatives with alkoxy group at the end of sidechain [6, 7] showed highest TS against OSCC cell lines, among 12 related compounds, and induced subG1 and G2/M arrest. TS was correlated with chemical descriptors that explain the 3D shape, electric state, and ionization potential. These two compounds can be potential candidates of lead compound for manufacturing new type of anticancer drugs. Further study is ongoing by our team, regarding combination of [6] or [7] and anticancer drugs against the human OSCC HSC-2 cell line.

Acknowledgements

This work was partially supported by KAKENHI from the Japan Society for the Promotion of Science (JSPS) (16K11519).

Footnotes

  • Author's Contributions

    M.T., S.N. performed all experiments. M.F. synthesized samples. N.O., K.B., Y.I. and H.S. performed the cell culture and apoptosis assays. J.N. and Y.U. performed the QSAR analysis. H.S., M.H. and H.W. wrote and reviewed the manuscript.

  • This article is freely accessible online.

  • Conflicts of Interest

    The Authors confirm that there are no known conflicts of interest associated with this publication and there was no significant financial support for this work that could have influenced its outcome.

  • Received May 9, 2020.
  • Revision received June 7, 2020.
  • Accepted June 24, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Kotake M
    1. Nozoe T,
    2. Asao T
    : Azulenes and heptafulvenes. In: Dai-Yuki Kagaku. Kotake M (ed.), Tokyo, Asakura-Shoten, Vol.13, pp. 439-534, 1960 (in Japanese).
    OpenUrl
    1. Nozoe T,
    2. Breslow R,
    3. Hafner K,
    4. Ito S,
    5. Murata I
    : Topics in Nonbenzenoid Aromatic Chemistry. Tokyo, Hirokawa Publ. Co., Vol I: pp. 1-295, 1973.
    OpenUrl
    1. Nozoe T,
    2. Breslow R,
    3. Hafner K,
    4. Ito S,
    5. Murata I
    : Topics in Nonbenzenoid Aromatic Chemistry. Tokyo, Hirokawa Publ. Co., Vol II: pp. 1-379, 1977.
    OpenUrl
  2. ↵
    1. Zeller KP
    : Methoden der organischen chemie. New York, Houben-Weyl, Band V/2c, pp. 127-418, 1985.
  3. ↵
    1. Nihei S,
    2. Sato J,
    3. Komatsu H,
    4. Ishida K,
    5. Kimura T,
    6. Tomita T,
    7. Kudo K
    : The efficacy of sodium azulene sulfonate L-glutamine for managing chemotherapy-induced oral mucositis in cancer patients: a prospective comparative study. J Pharm Health Care Sci 4: 20, 2018. PMID: 30123519. DOI: 10.1186/s40780-018-0114-2
    OpenUrl
  4. ↵
    1. Matsumoto K,
    2. Matsuo K,
    3. Yatagai N,
    4. Enomoto Y,
    5. Shigeoka M,
    6. Hasegawa T,
    7. Suzuki H,
    8. Komori T
    : Clinical evaluation of CO2 laser vaporization therapy for oral lichen planus: A single-arm intervention study. Photobiomodul Photomed Laser Surg 37(3): 175-181, 2019. PMID: 31050948. DOI: 10.1089/photob.2018.4559
    OpenUrl
  5. ↵
    1. Ayaz F,
    2. Yuzer A,
    3. Ince T,
    4. Ince M
    : Anti-cancer and anti-Inflammatory activities of bromo- and cyano-substituted azulene derivatives. Inflammation, 2020. DOI: 10.1007/s10753-020-01186-0
  6. ↵
    1. Sakai H,
    2. Misawa M
    : Effect of sodium azulene sulfonate on capsaicin-induced pharyngitis in rats. Basic Clin Pharmacol Toxicol 96(1): 54-59, 2005. PMID: 15667596. DOI: 10.1111/j.1742-7843.2005.pto960108.x
    OpenUrlPubMed
  7. ↵
    1. Kourounakis AP,
    2. Rekka EA,
    3. Kourounakis PN
    : Antioxidant activity of guaiazulene and protection against paracetamol hepatotoxicity in rats. J Pharm Pharmacol 49(9): 938-942, 1997. PMID: 9306266. DOI: 10.1111/j.2042-7158.1997.tb06140.x
    OpenUrlPubMed
    1. Pratsinis H,
    2. Haroutounian SA
    : Synthesis and antioxidant activity of 3-substituted guaiazulene derivatives. Nat Prod Lett 16(3): 201-205, 2002. PMID: 12049221. DOI: 10.1080/10575630290013585
    OpenUrlPubMed
  8. ↵
    1. Mangkhalthon AP,
    2. Teerakapong A,
    3. Tippayawat P,
    4. Morales NP,
    5. Morkmued S,
    6. Puasiri S,
    7. Priprem A,
    8. Damrongrungruang T
    : Anti-inflammatory effect of photodynamic therapy using guaiazulene and red lasers on peripheral blood mononuclear cells. Photodiagnosis Photodyn Ther 101747, 2020. PMID: 32200021. DOI: 10.1016/j.pdpdt.2020.101747
  9. ↵
    1. Kakei T,
    2. Matsumoto M,
    3. Kojima K,
    4. Suzuki R,
    5. Narita R
    : Guaiazulene mouthwash for diseases of the oral mucosa. Shikai Tenbo 63(4): 843-849, 1984. PMID: 6591496.
    OpenUrl
  10. ↵
    1. Zhai W,
    2. Liu J,
    3. Liu Q,
    4. Wang Y,
    5. Yang D
    : Rapid identification and global characterization of multiple constituents from the essential oil of Cortex Dictamni based on GC-MS. J Sep Sci 40(12): 2671-2681, 2017. PMID: 28493524. DOI: 10.1002/jssc.201700072
    OpenUrl
  11. ↵
    1. Uehara M,
    2. Minemura H,
    3. Ohno T,
    4. Hashimoto M,
    5. Wakabayashi H,
    6. Okudaira N,
    7. Sakagami H
    : In vitro antitumor activity of alkylaminoguaiazulenes. In Vivo 32(3): 541-547, 2018. PMID: 29695558. DOI: 10.21873/invivo.11273
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Wada T,
    2. Maruyama R,
    3. Irie Y,
    4. Hashimoto M,
    5. Wakabayashi H,
    6. Okudaira N,
    7. Uesawa Y,
    8. Kagaya H,
    9. Sakagami H
    : In vitro anti-tumor activity of azulene amide derivatives. In Vivo 32(3): 479-486, 2018. PMID: 29695549. DOI: 10.21873/invivo.11264
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Imanari K,
    2. Hashimoto M,
    3. Wakabayashi H,
    4. Okudaira N,
    5. Bandow K,
    6. Nagai J,
    7. Tomomura M,
    8. Tomomura A,
    9. Uesawa Y,
    10. Sakagami H
    : Quantitative structure-cytotoxicity relationship of azulene amide derivatives. Anticancer Res 39(7): 3507-3518, 2019. PMID: 31262875. DOI: 10.21873/anticanres.13497
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Anderson AG,
    2. Anderson RG
    : The reaction of azulenes with trifluoro- and trichloroacetic anhydride. J Org Chem 27(10): 3578-3581, 1962. DOI: 10.1021/jo01057a044
    OpenUrl
  15. ↵
    1. Okajima T,
    2. Kurokawa S
    : Facile conversion of 1-methyl group of guaiazuleue into 1-formyl group. Chem Lett 26(1): 69-70, 1997. DOI: 10.1246/cl.1997.69
    OpenUrl
  16. ↵
    1. Kantoh K,
    2. Ono M,
    3. Nakamura Y,
    4. Nakamura Y,
    5. Hashimoto K,
    6. Sakagami H,
    7. Wakabayashi H
    : Hormetic and anti-radiation effects of tropolone-related compounds. In Vivo 24(6): 843-851, 2010. PMID: 21164042.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Horikoshi M,
    2. Kimura Y,
    3. Nagura H,
    4. Ono T,
    5. Ito H
    : A new human cell line derived from human carcinoma of the gingiva. I. Its establishment and morphological studies. Nihon Koku Geka Gakkai Zasshi 20(2): 100-106, 1974. PMID: 4549822. DOI: 10.5794/jjoms.20.100
    OpenUrl
  18. ↵
    1. Fiori J,
    2. Teti G,
    3. Gotti R,
    4. Mazzotti G,
    5. Falconi M
    : Cytotoxic activity of guaiazulene on gingival fibroblasts and the influence of light exposure on guaiazulene-induced cell death. Toxicol In Vitro 25(1): 64-72, 2011. PMID: 20854889. DOI: 10.1016/j.tiv.2010.09.008
    OpenUrlPubMed
  19. ↵
    1. Majno G,
    2. Joris I
    : Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 146(1): 3-15, 1995. PMID: 7856735.
    OpenUrlPubMed
  20. ↵
    1. Wlodkowic D,
    2. Telford W,
    3. Skommer J,
    4. Darzynkiewicz Z
    : Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol 103: 55-98, 2011. PMID: 21722800. DOI: 10.1016/B978-0-12-385493-3.00004-8
    OpenUrlCrossRefPubMed
  21. ↵
    1. Yang CH,
    2. Horwitz SB
    : Taxol®: The first microtubule stabilizing agent. Int J Mol Sci 18(8): 1733, 2017. PMID: 28792473. DOI: 10.3390/ijms18081733
    OpenUrl
  22. ↵
    1. Iijima Y,
    2. Bandow K,
    3. Sano M,
    4. Hino S,
    5. Kaneko T,
    6. Horie N,
    7. Sakagami H
    : In vitro assessment of antitumor potential and combination Effect of classical and molecular-targeted anticancer drugs. Anticancer Res 39(12): 6673-6684, 2019. PMID: 31810932. DOI: 10.21873/anticanres.13882
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Takao K,
    2. Hoshi K,
    3. Sakagami H,
    4. Shi H,
    5. Bandow K,
    6. Nagai J,
    7. Uesawa Y,
    8. Tomomura A,
    9. Tomomura M,
    10. Sugita Y
    : Further quantitative structure-cytotoxicity relationship analysis of 3-styrylchromones. Anticancer Res 40(1): 87-95, 2020. PMID: 31892556. DOI: 10.21873/anticanres.13929
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. da Costa R,
    2. Passos GF,
    3. Quintão NLM,
    4. Fernandes ES,
    5. Maia JRLCB,
    6. Campos MM,
    7. Calixto JB
    : Taxane-induced neurotoxicity: pathophysiology and therapeutic perspectives. Br J Pharmacol, 2020. PMID: 32352155. DOI: 10.1111/bph.15086
    1. Pittman SK,
    2. Gracias NG,
    3. Fehrenbacher JC
    : Nerve growth factor alters microtubule targeting agent-induced neurotransmitter release but not MTA-induced neurite retraction in sensory neurons. Exp Neurol 279: 104-115, 2016. PMID: 26883566. DOI: 10.1016/j.expneurol.2016.02.010
    OpenUrl
    1. Rovini A,
    2. Savry A,
    3. Braguer D,
    4. Carré M
    : Microtubule-targeted agents: when mitochondria become essential to chemotherapy. Biochim Biophys Acta 1807(6): 679-688, 2011. PMID: 21216222. DOI: 10.1016/j.bbabio.2011.01.001
    OpenUrlPubMed
  25. ↵
    1. Iijima Y,
    2. Bandow K,
    3. Amano S,
    4. Sano M,
    5. Hino S,
    6. Kaneko T,
    7. Horie N,
    8. Sakagami H
    : Protection of bortezomib-induced neurotoxicity by antioxidants. Anticancer Res 40(7), 2020.
  26. ↵
    1. Sakagami H,
    2. Okudaira N,
    3. Masuda Y,
    4. Amano O,
    5. Yokose S,
    6. Kanda Y,
    7. Suguro M,
    8. Natori T,
    9. Oizumi H,
    10. Oizumi T
    : Induction of apoptosis in human oral keratinocyte by doxorubicin. Anticancer Res 37(3): 1023-1029, 2017. PMID: 28314260. DOI: 10.21873/anticanres.11412
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 40 (9)
Anticancer Research
Vol. 40, Issue 9
September 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antitumor Effects and Tumor-specificity of Guaiazulene-3-Carboxylate Derivatives Against Oral Squamous Cell Carcinoma In Vitro
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
18 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Antitumor Effects and Tumor-specificity of Guaiazulene-3-Carboxylate Derivatives Against Oral Squamous Cell Carcinoma In Vitro
MICHITO TERATANI, SHOUTA NAKAMURA, HIROSHI SAKAGAMI, MASAKAZU FUJISE, MASASHI HASHIMOTO, NORIYUKI OKUDAIRA, KENJIRO BANDOW, YOSUKE IIJIMA, JUNKO NAGAI, YOSHIHIRO UESAWA, HIDETSUGU WAKABAYASHI
Anticancer Research Sep 2020, 40 (9) 4885-4894; DOI: 10.21873/anticanres.14491

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Antitumor Effects and Tumor-specificity of Guaiazulene-3-Carboxylate Derivatives Against Oral Squamous Cell Carcinoma In Vitro
MICHITO TERATANI, SHOUTA NAKAMURA, HIROSHI SAKAGAMI, MASAKAZU FUJISE, MASASHI HASHIMOTO, NORIYUKI OKUDAIRA, KENJIRO BANDOW, YOSUKE IIJIMA, JUNKO NAGAI, YOSHIHIRO UESAWA, HIDETSUGU WAKABAYASHI
Anticancer Research Sep 2020, 40 (9) 4885-4894; DOI: 10.21873/anticanres.14491
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Avobenzone, Guaiazulene and Tioxolone identified as potent autophagy inducers in a high-throughput image based screen for autophagy flux
  • Google Scholar

More in this TOC Section

  • Apigenin-induced Apoptosis in Lung Adenocarcinoma A549 Cells: Involvement in IFNA2, TNF, and SPON2 With Different Time Points
  • Study of the Cytotoxic and Antitumor Effect of L-lysine-α-oxidase from Trichoderma harzianum Rifai
  • Damnacanthal Suppresses TCF4 Expression in Colorectal Cancer Cells
Show more Experimental Studies

Similar Articles

Keywords

  • QSAR
  • guaiazulene-3-carboxylate
  • OSCC
  • tumor-specificity
  • molecular shape
  • ionization potential
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire